CSF1R and B-cell chronic lymphocytic leukemia: Given the role of NLCs in CLL as well as possible therapeutic implications, we evaluated the impact of CSF1R inhibition using highly selective small-molecule inhibitors across a broad spectrum of primary CLL samples.